124 related articles for article (PubMed ID: 27574725)
1. Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer.
Francica P; Aebersold DM; Medová M
Biochem Pharmacol; 2017 Feb; 126():1-12. PubMed ID: 27574725
[TBL] [Abstract][Full Text] [Related]
2. Cellular senescence and cancer treatment.
Schmitt CA
Biochim Biophys Acta; 2007 Jan; 1775(1):5-20. PubMed ID: 17027159
[TBL] [Abstract][Full Text] [Related]
3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
4. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation.
Gewirtz DA; Holt SE; Elmore LW
Biochem Pharmacol; 2008 Oct; 76(8):947-57. PubMed ID: 18657518
[TBL] [Abstract][Full Text] [Related]
5. Exploiting tumor cell senescence in anticancer therapy.
Lee M; Lee JS
BMB Rep; 2014 Feb; 47(2):51-9. PubMed ID: 24411464
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization.
Bhattacharya P; Shetake NG; Pandey BN; Kumar A
Int J Radiat Biol; 2018 Jul; 94(7):628-644. PubMed ID: 29775397
[TBL] [Abstract][Full Text] [Related]
7. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
8. [The role of cellular senescence in carcinogenesis and antitumor therapy].
Mosieniak G; Strzeszewska A
Postepy Biochem; 2014; 60(2):194-206. PubMed ID: 25134355
[TBL] [Abstract][Full Text] [Related]
9. Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy.
Shabani M; Hojjat-Farsangi M
Curr Drug Targets; 2016; 17(14):1687-1703. PubMed ID: 26424402
[TBL] [Abstract][Full Text] [Related]
10. Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.
LaVallee TM; Alvarado D; Garton AJ; Trombetta ES; Gedrich R; McMahon G
Crit Rev Oncog; 2015; 20(5-6):485-508. PubMed ID: 27279243
[TBL] [Abstract][Full Text] [Related]
11. New targeted therapies for gastric cancer.
Asaoka Y; Ikenoue T; Koike K
Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
[TBL] [Abstract][Full Text] [Related]
12. Methods of cellular senescence induction using oxidative stress.
Wang Z; Wei D; Xiao H
Methods Mol Biol; 2013; 1048():135-44. PubMed ID: 23929103
[TBL] [Abstract][Full Text] [Related]
13. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence.
Larsson LG
Semin Cancer Biol; 2011 Dec; 21(6):367-76. PubMed ID: 22037160
[TBL] [Abstract][Full Text] [Related]
14. Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.
Honoki K; Tsujiuchi T
Expert Rev Anticancer Ther; 2013 Aug; 13(8):983-96. PubMed ID: 23984899
[TBL] [Abstract][Full Text] [Related]
15. Cellular senescence in cancer treatment: friend or foe?
Kahlem P; Dörken B; Schmitt CA
J Clin Invest; 2004 Jan; 113(2):169-74. PubMed ID: 14722606
[TBL] [Abstract][Full Text] [Related]
16. Checks and balances: interplay of RTKs and PTPs in cancer progression.
Sastry SK; Elferink LA
Biochem Pharmacol; 2011 Sep; 82(5):435-40. PubMed ID: 21704606
[TBL] [Abstract][Full Text] [Related]
17. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
18. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.
Laine A; Westermarck J
Clin Cancer Res; 2014 Jul; 20(14):3644-50. PubMed ID: 24788101
[TBL] [Abstract][Full Text] [Related]
20. IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2.
Hubackova S; Kucerova A; Michlits G; Kyjacova L; Reinis M; Korolov O; Bartek J; Hodny Z
Oncogene; 2016 Mar; 35(10):1236-49. PubMed ID: 25982278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
